12:04 , May 24, 2018 |  BioCentury  |  Finance

Chasing China

While Nan Fung Life Sciences had planned to establish a longer track record in biotech investments before launching its first China-focused fund, the group accelerated its plans to capitalize on the growing Chinese biotech industry....
22:50 , May 11, 2018 |  BioCentury  |  Finance

Watching the wave

After raising the largest ever series B round for a Chinese biotech, CStone Pharmaceuticals Co. Ltd. should have enough funding to run four pivotal cancer studies in parallel as it monitors the performance of the...
18:12 , May 11, 2018 |  BC Week In Review  |  Financial News

Chinese immuno-oncology play CStone raises $260M

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) raised on May 8 $260 million in a series B round led by new investor GIC Private. CStone said the round is the largest series B ever for a...
16:38 , May 9, 2018 |  BC Extra  |  Financial News

Chinese immuno-oncology play CStone raises $260M

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) raised $260 million in a series B round led by new investor GIC Private. CStone said the round is the largest series B ever for a Chinese biopharma. New investors...
19:57 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Daiichi reports Phase IIIb data for edoxaban in cancer-associated VTE

Daiichi Sankyo Co. Ltd. (Tokyo:4568) said once-daily oral edoxaban (DU-176b) met the primary endpoint of non-inferiority to standard of care (SOC) dalteparin in the incidence of a composite of recurrent venous thromboembolism (VTE) or major...
19:54 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

Xarelto lowers CV risk, ups major bleeds in Phase III for artery disease

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) reported full data from the Phase III COMPASS trial showing that twice-daily 2.5 mg oral Xarelto rivaroxaban (BAY 59-7939) plus once-daily 100 mg...
22:59 , Aug 28, 2017 |  BC Extra  |  Clinical News

Xarelto lowers CV risk, ups major bleeds in artery disease

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) released full data from the Phase III COMPASS trial showing that twice-daily 2.5 mg oral Xarelto rivaroxaban plus once-daily 100 mg aspirin reduced...
01:01 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Xarelto sNDA gets FDA Priority Review for VTE

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) said FDA accepted and granted Priority Review to an sNDA for a once-daily 10 mg dose of Xarelto rivaroxaban (BAY 59-7939) to reduce...
19:58 , May 5, 2017 |  BC Week In Review  |  Clinical News

Daiichi begins Ph IIIb of Lixiana to treat AF

Daiichi Sankyo Co. Ltd. (Tokyo:4568) began the Phase IIIb ENVISAGE-TAVI AF trial to evaluate Lixiana edoxaban (DU-176b) in patients with atrial fibrillation (AF). The open-label, international trial will compare once-daily oral Lixiana vs. a vitamin...
22:38 , Apr 26, 2017 |  BC Extra  |  Company News

Chinese PE firm to acquire Epigenomics

A subsidiary of Chinese private equity firm Cathay Fortune International Co. Ltd. will acquire molecular diagnostics company Epigenomics AG (Xetra:ECX; OTCQX:EPGNY) for €7.52 per share, or about €171 million ($185.6 million) in cash. The subsidiary, Blitz...